ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced the initiation of CLARITY, a Phase II study to evaluate pimavanserin for adjunctive treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE